Insmed Inc
NASDAQ:INSM

Watchlist Manager
Insmed Inc Logo
Insmed Inc
NASDAQ:INSM
Watchlist
Price: 195.87 USD 0.32%
Market Cap: 41.8B USD

Operating Margin
Insmed Inc

-221.5%
Current
-215%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-221.5%
=
Operating Profit
-990.3m
/
Revenue
447m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Insmed Inc
NASDAQ:INSM
41.6B USD
-222%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
392.9B USD
33%
US
Amgen Inc
NASDAQ:AMGN
170.1B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
150.9B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.5B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.6B USD
28%
AU
CSL Ltd
ASX:CSL
89.1B AUD
26%
NL
argenx SE
XBRU:ARGX
46B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.8B USD
8%
No Stocks Found

Insmed Inc
Glance View

Insmed Inc., a biopharmaceutical company rooted in Bridgewater, New Jersey, emerged from the desire to tackle serious and rare diseases with potentially groundbreaking therapies. The company's journey is defined by its commitment to developing novel treatments for patients suffering from conditions often overlooked by mainstream pharmaceutical firms. At the heart of Insmed's operations lies its pursuit of treatments for rare pulmonary diseases, with its flagship product, ARIKAYCE, exemplifying their mission in action. Approved by the FDA for treating Mycobacterium avium complex (MAC) lung disease, ARIKAYCE represents a significant breakthrough, addressing a critical unmet medical need. By targeting specific patient populations with limited options, Insmed taps into niche markets where they face less competition and, simultaneously, a profound opportunity to make a meaningful impact on patient lives. The company's strategy revolves around leveraging innovative science to build a pipeline rich with potential treatments across various stages of clinical development. It focuses on expanding the use of ARIKAYCE, while also exploring new formulations and indications. Insmed channels resources into research and development, securing patent protections and establishing a robust global presence to ensure its therapies reach the patients who need them. Revenues are primarily generated through product sales, with ARIKAYCE as the cornerstone, alongside strategic partnerships and collaborations that allow for shared expertise and resources. This business model positions Insmed not only as a healthcare provider but as a key player in the biopharmaceutical industry, striving to transform lives by bringing forth meaningful medical innovations.

INSM Intrinsic Value
109.32 USD
Overvaluation 44%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-221.5%
=
Operating Profit
-990.3m
/
Revenue
447m
What is the Operating Margin of Insmed Inc?

Based on Insmed Inc's most recent financial statements, the company has Operating Margin of -221.5%.

Back to Top